

Santen to Establish a Corporate Venture Capital Fund in the United States

May 1, 2017, Osaka, Japan – Santen Pharmaceutical Co., Ltd. (“Santen”) today announced plans to establish a corporate venture capital fund (“fund”) to be based in Emeryville, California, United States. Santen aims to strengthen the company’s strategic investment activities through the fund which will invest in early stage companies developing differentiated technologies in new and emerging pharmaceutical and non-pharmaceutical treatments for ophthalmic conditions.

The fund will be established with a total fund size of US\$50 million and will be wholly owned by Santen Group. The purpose of the fund is to create valuable synergies with early stage companies developing differentiated technologies as ophthalmic treatments in order to enhance Santen’s R&D pipeline and contribute to our goal of improving the quality of life of patients suffering from eye diseases.

The fund establishes a framework for Santen’s syndicated venture investments which began in 2015. Of the pharmaceutical products being made available around the world, the percentage of pharmaceuticals originating from venture-backed companies is increasing steadily. Santen will utilize its deep expertise and network built over a long history as an ophthalmic specialty company, to strengthen access to the venture market and allow Santen to best contribute to meet the unmet treatment needs within the ophthalmology segment.

About Santen

As a specialty company dedicated to the ophthalmic field, Santen carries out research, development, marketing, and sales of pharmaceuticals and devices. Santen is the market leader in Japan for prescription ophthalmic pharmaceuticals and sells products in over 50 countries. As a leading company in the field of ophthalmology, Santen aims to contribute to society by supplying valuable products and services to satisfy unmet medical needs. For more details, please see Santen’s website (www.santen.com).

Santen Forward-looking Statements

Information provided in this press release contains so-called “Forward-looking Statements.” The realizations of these forecasts are subject to risk and uncertainty from various sources. Therefore, please note that the actual results may differ significantly from the forecasts. Business performance and financial condition are subject to the effects of change in regulations made by the governments of Japan and other nations concerning medical insurance, drug pricing and other systems, and to fluctuations in market variables such as interest rates and foreign exchange rates.

Contact

Santen Pharmaceutical Co., Ltd.

Christopher Hohman, General Manager, Corporate Communications Group

E-mail: ir@santen.co.jp Tel: +81-6-4802-9360